Chronic kidney disease-mineral and bone disorder

Defeat Duchenne Canada and Parent Project Muscular Dystrophy Award $300,000 (USD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility

Retrieved on: 
Friday, November 3, 2023
Fertility, Steroid, Children's Hospital of Eastern Ontario, CHEO, Research, APRN, Louisiana Family Forum, Canada Research Chair, Bone, Endocrinology, Organization, Chronic kidney disease-mineral and bone disorder, University of Ottawa Heart Institute, Adrenal insufficiency, Vamorolone, Prednisone, PPMD, Male, Growth, Gender identity, Muscle weakness, University of Ottawa, Risk, Consortium, Duchenne muscular dystrophy, Partnership, DRS, University, Osteoporosis, Weakness, USD, Puberty, Education, DMD, Fracture, Muscular dystrophy, Hospital, Calvarial doughnut lesions-bone fragility syndrome, Human, Nursing, Dietary supplement, Medical device, Pediatrics, Duchenne

WASHINGTON and OTTAWA, ON, Nov. 3, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Defeat Duchenne Canada, Canada's leading charity fighting to defeat Duchenne, today announced a collaborative research award of $300,000 (USD) in support of two Clinical Fellowships in Duchenne Endocrinology and Bone Fragility. The three-year award will sponsor the extended fellowship of Dr. Kim Phung, as well as new fellow Dr. Rana Halloun, under the guidance of Dr. Leanne Ward, Professor of Pediatrics and Research Chair in Pediatric Bone Disorders at the University of Ottawa.

Key Points: 
  • Duchenne is the most common muscular dystrophy in children, affecting approximately one in 5,000 live male births.
  • Duchenne is caused by a change in the dystrophin gene that leads to progressive muscle weakness.
  • In 2021, Dr. Phung was awarded a two-year fellowship in pediatric endocrine and bone diseases at the University of Ottawa, with specific focus on endocrine and bone complications of Duchenne.
  • Ward and Phung will delve into the latest developments and crucial topics related to bone health, growth, puberty, and adrenal insufficiency for Duchenne muscular dystrophy.

Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Clinical Trials, Medicinal chemistry, Bone cancer in cats and dogs, Surgeon, Therapy, Drug discovery, Head, Osteosarcoma, Bone, Research, Merck & Co., Factorization of polynomials, Prostaglandin, Former, Metastasis, New York Blood Center, Patient, CBO, Chronic kidney disease-mineral and bone disorder, Chief financial officer, Merck, EP4, Elective surgery, Safety, Pharmaceutical industry, Medical imaging, Dentistry

Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.

Key Points: 
  • Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.
  • The bone is a complex, dynamic tissue with unique properties that make it a formidable challenge for drug efficient penetration.
  • The company successfully dosed the first patients via subcutaneous injection in a Phase 1 study evaluating MES1022, a bone-selective EP4 receptor agonist prodrug they are developing for bone regeneration, with the first application for accelerating healing of bone fractures.
  • “MES1022 is well-positioned to be the first therapy that mimics and enhances the natural processes the body uses to stimulate bone repair and healing.

Phoenix Children's Expands Pediatric Orthopedic Surgery Team with Hire of Globally Renowned Brittle Bone Expert

Retrieved on: 
Monday, September 11, 2023
American Society for Bone and Mineral Research, Sports medicine, Missouri State University, University, Nationwide Children's Hospital, Body composition, University of Nebraska Medical Center, Phoenix Children's Hospital, Elective surgery, University of Nebraska–Lincoln, Quality of life, Hope, Nebraska Medicine, Osteoblast, Osteogenesis imperfecta, Collagen, type I, alpha 1, MBA, Research, Chronic kidney disease-mineral and bone disorder, National Association Medical Staff Services, Business administration, Jansen, Diving Medical Advisory Council, MD, Patient, Lincoln, Nebraska, Medical Center, Hospital, AI, Saint Louis University, Society, Dentistry, Nursing, Medical device, Orthopedic surgery, Child

Maegen Wallace, MD, MBA , a pediatric orthopedic surgeon and expert in osteogenesis imperfecta, or brittle bone disease, joined the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's last month.

Key Points: 
  • Maegen Wallace, MD, MBA , a pediatric orthopedic surgeon and expert in osteogenesis imperfecta, or brittle bone disease, joined the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's last month.
  • At the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's, Dr. Wallace will focus on lower-extremity issues, osteogenesis imperfecta and other rare skeletal diseases .
  • On the research front, she will continue her work to define best clinical practices for patients with brittle bone disease and uncover new treatment options.
  • "Phoenix Children's emphasis on research and the chance to work once again with Dr. Halanski are what drew me to Phoenix Children's," said Dr. Wallace.

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

Retrieved on: 
Monday, June 12, 2023
1991 World Sportscar Championship, PD, IV, ASSIST, Cohort, Pharmacokinetics, Research, Part, Immunoglobulin A, Biomarker, EDT, ERA, Congress, Proteinuria, Acquisition, HIV disease progression rates, Patient, CEST, Kidney, IgA nephropathy, Immunoglobulin G, Therapy, Chronic kidney disease-mineral and bone disorder, Kidney disease, Safety, Novartis, Pharmaceutical industry, Vaccine, Health insurance, Chinook

Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).

Key Points: 
  • Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
  • Key highlights from the presentation include the following:
    Patients in Cohort 1 initially received a 450mg intravenous (IV) dose of zigakibart every two weeks.
  • Cohort 1 enrolled 10 patients, of which two patients withdrew from the study for reasons unrelated to study drug, and eight patients continued receiving treatment.
  • Of all 40 patients enrolled in both Cohorts 1 and 2:
    There were no anti-drug antibodies observed in any patients.

Bone and Mineral Diagnostic Testing Global Market Report 2023: Worldwide Prevalence of Vitamin D Deficiencies Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, May 5, 2023
Health, Biotechnology, Urbanization, Prevalence, ELISA, Research, Government, Organization, CLIA, Chronic kidney disease-mineral and bone disorder, Diagnosis, Market trend, R, POC, Automation, Medical device, Medical imaging, Dietary supplement, Application, Others

The global bone and mineral diagnostic testing market size reached US$ 1.01 Billion in 2022.

Key Points: 
  • The global bone and mineral diagnostic testing market size reached US$ 1.01 Billion in 2022.
  • Bone and Mineral Diagnostic Testing Market Trends:
    A considerable increase in the incidences of bone-related diseases on the global level is a significant factor driving the market.
  • The report has provided a detailed breakup and analysis of the bone and mineral diagnostic testing market based on the product.
  • The report has provided a detailed breakup and analysis of the bone and mineral diagnostic testing market based on the test type.

Radiology Information Systems Market Expected to Reach USD 1,746 Million by 2030: Verified Market Research®

Retrieved on: 
Tuesday, March 28, 2023
Siemens Healthineers, Component, Epic Systems, GE HealthCare, Prevalence, Health, Information technology, McKesson Corporation, Cancer, RIS, Research, USD, Compound annual growth rate, SWOT, Cerner, Patient, Philips, Allscripts, Chronic kidney disease-mineral and bone disorder, Geography, Growth, Information system, Retail, Medical imaging

JERSEY CITY, N.J., March 28, 2023 /PRNewswire/ --  The global Radiology Information Systems Market is projected to grow at a CAGR of 7.8% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 824.55 Million in 2021 and is expected to reach USD 1,746 Million by the end of the forecast period.

Key Points: 
  • The report also provides an in-depth analysis of the global Radiology Information Systems Market, including its growth prospects, market trends, and market challenges.
  • The report reveals that the market was valued at USD 824.55 Million in 2021 and is expected to reach USD 1,746 Million by the end of the forecast period.
  • The report provides a detailed and exhaustive analysis of the global radiology information systems market, including market size, market share, market ranking analysis, key segments, trends, drivers, restraints, and competitive landscape.
  • Based on the research, Verified Market Research® has segmented the global Radiology Information Systems Market into End User, Component, And Geography.

Radiology Information Systems Market Expected to Reach USD 1,746 Million by 2030: Verified Market Research®

Retrieved on: 
Tuesday, March 28, 2023
Siemens Healthineers, Component, Epic Systems, GE HealthCare, Prevalence, Health, Information technology, McKesson Corporation, Cancer, RIS, Research, USD, Compound annual growth rate, SWOT, Cerner, Patient, Philips, Allscripts, Chronic kidney disease-mineral and bone disorder, Geography, Growth, Information system, Retail, Medical imaging

JERSEY CITY, N.J., March 28, 2023 /PRNewswire/ --  The global Radiology Information Systems Market is projected to grow at a CAGR of 7.8% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 824.55 Million in 2021 and is expected to reach USD 1,746 Million by the end of the forecast period.

Key Points: 
  • The report also provides an in-depth analysis of the global Radiology Information Systems Market, including its growth prospects, market trends, and market challenges.
  • The report reveals that the market was valued at USD 824.55 Million in 2021 and is expected to reach USD 1,746 Million by the end of the forecast period.
  • The report provides a detailed and exhaustive analysis of the global radiology information systems market, including market size, market share, market ranking analysis, key segments, trends, drivers, restraints, and competitive landscape.
  • Based on the research, Verified Market Research® has segmented the global Radiology Information Systems Market into End User, Component, And Geography.

Tendonitis Treatment (Therapy, Surgery) Market Analysis Report 2022: A $280+ Billion Market by 2030 - Pricing Analysis, Product Pipeline Analysis, & Industry Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Surgery, Health, Osteoporosis, Health, Incidence, Tennis elbow, Prevalence, Travel, Condition, Achilles tendinitis, Injury, Treatment, Sport, Diabetes, Osteoarthritis, USD, Growth, Investment, Tendinopathy, COVID-19, Chronic kidney disease-mineral and bone disorder, Arthritis, Dentistry, Pharmaceutical industry, Health insurance

In addition, the rising incidence of occupational injuries is anticipated to contribute to the development and growth of the industry over the forecast period.

Key Points: 
  • In addition, the rising incidence of occupational injuries is anticipated to contribute to the development and growth of the industry over the forecast period.
  • The growing global geriatric population is susceptible to bone disorders, diabetes, arthritis, osteoarthritis, osteoporosis, or tendonitis.
  • Industry participants that are constantly innovating advanced therapies and technologies in managing tendonitis are also contributing to the market growth.
  • Growing investments, industry collaborations, and increasing favorable government support are other key factors accelerating market growth.

Global Renal Osteodystrophy Market Research Report 2022-2028 Featuring Major Players - Amgen, Asahi Kasei, and B. Braun Medical, Baxter International, & DaVita - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Health, General Health, Baxter International, AstraZeneca, Prevalence, Renal osteodystrophy, Cancer, Growth, Government, Adoption, PKD, Goodpasture syndrome, Syringe, Patient, Chronic kidney disease-mineral and bone disorder, Ajinomoto, Chronic kidney disease, Dapagliflozin, Parathyroidectomy, Amgen, Ageing, Alport syndrome, Research, List, Philippine Council of Evangelical Churches, WHO, Incidence, Kidney transplantation, Hypertension, Atherosclerosis, B. Braun, Pharmaceutical industry, Medical device, Marketing

The "Global Renal Osteodystrophy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Osteodystrophy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global renal osteodystrophy market is anticipated to grow at a considerable growth during the forecast period.
  • The global renal osteodystrophy market is segmented on the basis on diagnosis method, and treatment.
  • The major companies serving the global renal osteodystrophy market are Amgen Inc., Asahi Kasei Corp., and B. Braun Medical, Baxter International Inc., DaVita Inc., and others.

Dr. Brett King Joins BiologicsMD as Senior Scientific Advisor and Member of the Scientific Advisory Board

Retrieved on: 
Tuesday, October 18, 2022
Janus, Yale University, Female, Yale School of Medicine, Skin, Bone, Hospital, Woman, Infection, Degenerative disease, Membrane protein, Patient, Drug development, Eyebrow, Thrombosis, Hair, Hair loss, Research, Malignancy, Man, Massachusetts General Hospital, Mortality, Cancer, Vitiligo, Coronavirus Scientific Advisory Board (Turkey), University, Immune system, Alopecia areata, Doctor of Philosophy, MD, Spinal fusion, Atopic dermatitis, Board, CEO, Associate, Board of directors, Stanford University, Baricitinib, Scalp, JAK, Chronic kidney disease-mineral and bone disorder, Eyelash, Male, Management, Medical device, Pharmaceutical industry, Vaccine, Dermatology, HAVEN

NEW HAVEN, Conn., Oct. 18, 2022 /PRNewswire/ -- BiologicsMD, a preclinical therapeutic development company focused on highly-targeted treatments for hair loss and bone disorders, announced today the appointment of Brett King, MD, PhD, Associate Professor of Dermatology at Yale Medical School, as a Senior Scientific Advisor to the company's management team and Board of Directors.

Key Points: 
  • As the Senior Scientific Advisor, Dr. King will also serve as a member of BiologicsMD's Scientific Advisory Board.
  • Dr. Brett King has more than 10 years of clinical research and medical practice experience in the field of alopecia areata.
  • "Having Dr. King join BiologicsMD as our Senior Scientific Advisor is a testament to our progress to date," stated J. David Owens, CEO of BiologicsMD.
  • BiologicsMD is a therapeutic development company focused on developing targeted treatments of hair loss disorders, as well as severe bone disorders.